ABSORB Post-Approval Clinical Study
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Ischaemic heart disorders
- Focus Adverse reactions
- Sponsors Abbott Vascular
- 09 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Aug 2017 Planned number of patients changed from 3000 to 2000.
- 02 Aug 2017 Planned initiation date changed from 1 Nov 2016 to 1 Aug 2017.